 |
2003
OMIG, Abstract 14
OMIG
Main Page | 2003
Abstracts | <
Previous | Next>
Will
Voriconazole Become the Antifungal of Choice In the treatment of
Corneal Yeast Infection?
M. Shah, D. Ritterband, M. Rhee, T. Kaiura, W. Perez, R. Koplin.
J. Seedor. The New York Eye and Ear Infirmary, New York, New York,
and New York Medical College, Valhalla, New York.
Purpose:
To determine the in vitro susceptibilities of ocular yeast isolates
to amphotericin B and voriconazole, a new antifungal agent approved
for systemic use.
Methods: 25 Candida species isolated from corneal
infection or corneal rim culture archived at the New York Eye and
Ear Infirmary were tested using E-test strips of amphotericin B
and voriconazole to determine the MIC. 17 C.albicans, 6 C.parapsilosis,
one C.glabrata, and one C.zeylanoides were tested. The Candida species
were incubated for 24 hours on Sabouraud dextrose agar (BBL). A
0.5 McFarland turbidity was achieved in 0.85% NaCI. A sterile swab
was dipped in the inoculum suspension and any excess fluid pressed
out. The inoculum was carefully swabbed on Mueller-Hinton agar (BBL)
in 3 directions to achieve even growth. The media absorbed any additional
moisture for 15 minutes before E-test placement. Culture plates
were then placed in a plastic bag to control incubator moisture
and incubated at 35oC for 24 to 48 hours. The MIC was read at the
point where the inhibition ellipse intersected the scale on the
strip.
Results: MICs were lower for voriconazole in 14
of 17 C.albicans species, 5 of 6 C.parapsilosis species, and for
the one species of C.glabrata and C.zeylanoides compared to amphotericin
B.
Conclusions: Our study suggests that voriconazole,
a second generation triazole, has in vitro effectiveness against
ocular yeast isolates. The potential clinical effectiveness of voriconazole
awaits further investigation.
OMIG
Main Page | 2003
Abstracts | <
Previous | Next>
|
|
|
